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Conflicting results have been reported concerning the 
association between high age and response to influenza 
vaccines. Some authors have found a reduced response in 
aged subjects, others have found no difference or even better 
results as compared with younger control subjects. 
Seventeen papers were selected from international literature 
published in the period 1968-1988 for a review of the 
anti-haemagglutinin-lgG sero-response following vaccina- 
tion: among 30 cases in which vaccine components could 
be studied independently, ten revealed a better immune 
response in young subjects than in the elderly, four found 
more favourable results in the elderly, and 16 could not 
detect any significant between-group-differences, th  latter 
most probably because of a high type-2-error. Nine of 
these 16 cases tended to favour young subjects. These 
results were relativated by the finding that each paper had 
at least one of three methodological limitations: (1) the 
failure to exclude subjects with illnesses or using drugs 
influencing the immune system, (2) the failure to 
exclude subjects with previous vaccinations against influenza, 
(3) the failure to exclude subjects with high prevaccination 
antibody titres. The direction of these biases is such that 
failure to address any one issue will lead to an 
underestimate of the response of aged subjects. In view of 
the failure to control these biases, it was not surprising 
that the papers reviewed presented a heterogeneous 
picture. Thus, the association between high age per se and 
response to influenza vaccines, i f  any, has not yet been 
established. Suggestions are made for future studies in 
which admission criteria should control health state and 
previous exposure to influenza ntigens. 
Introduction 
The proportion of people older than 60 years within the 
total population of developed countries is rapidly 
growing; the control of disorders related to higher age 
will increasingly become a focus of the entire health 
system. Human influenza viruses, naturally occurring 
during pandemics (influenza A) and epidemics (influenza 
A and B) cause significant excess morbidity and mortality 
in the elderly 1'2, not only in those with underlying 
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age-related chronic diseases, but also in apparently 
healthy subjects 3'4. Thus, prevention of influenza virus 
infections in the aged would substantially contribute to 
longevity and state of health. However, active immuniz- 
ation with currently available whole virus, split and 
subunit vaccines has several draw-backs: the effectiveness 
of these vaccines is dependent upon the continuously 
occurring antigenic drift or suddenly occurring antigenic 
shift of the membrane proteins of the influenza viruses, 
and they usually stimulate a short-life antibody response 
only. These facts have led to the recommendation to 
repeat vaccination annually. Moreover, published reports 
suggest, o various degrees, a limited efficacy of vaccines 
to protect aged subjects from influenza infection. 
In principle, there are three ways to determine the 
efficacy of a given vaccine in human beings: (1) the 
experimental trial, (2) the field trial and (3) the immune 
response study. 
1 In experimental trials, pathogenic effects are recorded 
in a vaccinated and unvaccinated group after challenge 
with a live pathogen. Experimental trials have been 
performed inhealthy children and young adult volunteers 
with both wild or attenuated influenza strains (see Refs 
5 and 6). It is evident that such a study design is 
impossible in aged populations. 
2 In field trials, the challenge occurs by exposition of 
subjects to the natural field pathogen i the environment. 
Well-known general and methodological problems of 
field trials with naturally occurring influenza viruses 
include unpredictability of the time of its occurrence, 
antigenic differences between the vaccine strains and 
epidemic viruses, possible differences in the exposure 
rates of groups to be compared, and possible mis- 
diagnoses of cases, if not laboratory-confirmed, because 
of the broad variety of other respiratory pathogens 
causing influenza-like symptoms. Special ethical problems 
arise in the aged. Since the benefits of influenza vaccines 
have been established in the sixties T, ethical reasons have 
limited the performance offield trials because of the risk 
to unvaccinated control subjects. As a consequence, most 
of the studies dealing with influenza-associated morbidity 
and mortality of vaccinated and unvaccinated aged 
populations are retrospective and/or suffer from a 
variety of serious methodological flaws. 
Strassburg et al. 8 reviewed 17 papers reporting 
influenza outbreaks in the aged and the effectiveness of
influenza vaccination, during a period from 1967/68 to 
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1982/83 and found important differences in study 
populations, vaccines, methodology and, as a conse- 
quence, levels of vaccine effectiveness. Despite these. 
restrictions, they estimated average ffectiveness rates for 
morbidity and mortality, respectively. While reduction 
of mortality in vaccinated subjects, as compared to 
unvaccinated controls, was calculated as being 67%, 
reduction of morbidity was found to be much lower 
(23%). However, experimental nd field trials in young, 
healthy adults in various epidemiological settings, using 
various vaccines, have repeatedly revealed much higher 
rates for reduction of morbidity: 60-90% (for review see 
Ref. 9). Although comparison of such values should be 
made very carefully, it could appear that young subjects 
are better protected than the aged. Among the factors 
which may contribute to a possibly impaired protection 
rate in the aged, a direct, age-related impairment of the 
immunological response to vaccines is to be discussed. 
3 The immune response study determines immunological 
changes after vaccination (mostly antibody production), 
which are thought to be associated with protection 
against he pathogen. The various methodological nd 
ethical problems associated with field trials may be 
avoided. It is essential, of course, that the affirming 
variables for assessing the protective properties of the 
vaccine have been sufficiently established by experimental 
trials and field observations with regard to natural 
infection. 
It is well known that serum IgG antibody against he 
viral haemagglutinin (HA) plays a major role in 
protection against influenza 1°'a1: in high concentrations, 
it provides resistance to acquisition of infection (total 
protection). In lower concentrations, it prevents or 
ameliorates disease after infection in a substantial number 
of cases (partial protection). Many authors define a 
quantitative protection threshold, i.e. a pre-exposition 
titre beyond which it is highly unlikely to acquire an 
infection or to develop illness. Thus, anti-HA serum 
antibody is a predictor of protection and a measure of 
vaccine efficacy, which makes immune response studies 
a good and practical alternative to field trials. 
In the present paper, available studies dealing with the 
anti-HA serum antibody response in elderly subjects 
upon immunization with inactivated influenza vaccine, 
are reviewed in an attempt o obtain insight into the 
correlation between high age and sero-response. The 
collected information should stimulate further research 
which may lead to improved policies for the use of current 
vaccines in the elderly or to the development ofnew types 
of vaccines. 
For reasons discussed later we did not apply quanti- 
tative methods for literature review to construct statistical 
summaries and comparisons of studies (meta-analysis 12)
but chose a traditional narrative approach (qualitative 
tally), though realizing its limitations ~3. However, we 
have attempted to obey the strict criteria for meta- 
analyses as established by Sachs et al. 14. 
Materials and methods 
Criteria for selection of  papers and source 
of  literature 
Age of study subjects. According to WHO practice ~5, 
the following terminology for chronological age is 
commonly used: 45-59 years, middle age; 6(~74 years, 
elderly; 75-89 years, aged; 90 or more years, very old. 
However, chronological age is not always a good 
indicator of biological age, i.e. the decline in the 
physiological ability to react appropriately to environ- 
mental stimuli 16. The process of biological aging is 
heterogeneous and occurs at different rates in individuals. 
For reasons of convenience and in spite of its arbitrary 
character, we used the terms 'elderly', 'aged' and 'very 
old' synonymously and selected papers dealing with 
persons predominantly above 60 years of age (aged 
groups), and control subjects younger than 60 years of 
age (young groups). 
Biological predictor of protection, vaccines, tudy design 
and laboratory tests. As outlined above, the production 
of serum antibody against viral haemagglutinin was 
chosen as a predictor and measure of vaccine efficacy. 
The induction of this antibody is strongly induced, apart 
from natural infection, by immunization with inactivated 
(whole virus, split or subunit) vaccines, but less so by 
experimental live vaccines whose protective effects 
may predominantly be caused by stimulation of local 
immunity 17. We did not include papers on these latter 
vaccines. 
Any study design was accepted which included the 
drawing of two blood specimens, one before and a second 
after vaccination. Booster immunizations were not 
included. Any laboratory test detecting antibody against 
viral haemagglutinin was accepted. Tests dealing with 
antibodies directed against other viral proteins (neur- 
aminidase, core) or measuring cellular immunity were 
not included, in view of their unknown association with 
protection. 
Year of performance of the studies. The impure and 
highly reactogenic influenza vaccines used during the 40s, 
50s and 60s were of variable potency. It did not seem 
appropriate for us to include this early vaccine period in 
our survey. At the end of the 60s, a new generation of 
highly purified, hardly reactogenic and potent whole- 
virus vaccines became available 1s'19, followed by split 
and subunit vaccines in the 70s. Coincidentally, in 1968 
a new epidemiological situation occurred with the 
pandemic emergence of the influenza A-H3N2 subtype. 
Therefore, we only included studies performed from 1968 
onwards. 
Source of literature. English-language papers mentioned 
in the monthly 'Influenza Bibliography' of the Medical 
Research Council and the WHO World Influenza Centre, 
published by the Medical Research Council Library, 
National Institute for Medical Research, Mill Hill, 
London, UK, and the databases of the library computer 
system of the Medical Faculty of the Erasmus University 
Rotterdam were searched for the combination of the 
keywords 'influenza' and 'vaccination'. From these 
sources, papers were selected using the following criteria: 
age stratification ofstudy subjects, type of vaccines, study 
design, laboratory tests, and year of performance of the 
study; The search was finished in December 1988. 
Serological response and statistical calculations 
Serological response may be expressed using one or 
more of the following parameters: (1) the mean fold 
increase (MFI), i.e. the difference between thc logarithm 
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of mean titres of post- and prevaccination sera, (2) the 
protection rate (PR), i.e. the proportion of subjects 
exceeding a given protection threshold after vaccination, 
(3) the response rate (RR), i.e. the proportion of subjects 
who show an at least four-fold titre increase 2°'21 after 
vaccination. 
The quantities corresponding with these parameters 
were either taken directly from the selected papers, or 
recalculated from their original data if given, or derived 
from appropriate tables or figures as presented in the 
original papers. For calculation of the protection rate, 
the protection threshold as given by the authors was 
used, or, if not available in the paper, a titre of 
36_4011,22,23 when a standard microtitre haemagglutin- 
ation inhibition technique had been performed. As 
outlined later, previous antibody against the vaccine 
component is a factor strongly influencing the production 
of new homologous antibody upon vaccination. While 
the protection rate is based on previously unprotected 
subjects, it has been attempted, for the two other 
parameters (MFI and RR), to retrospectively stratify the 
prevaccination state of the study groups as unprotected 
(including seronegative and low seropositive subjects) or 
protected subjects prior to vaccination, and to recalculate 
the quantities for unprotected subjects only. All recalcula- 
tions are reported in the Tables. 
For statistical nalysis, the absolute differences between 
the seroresponse parameters ofaged •and young subjects 
were recalculated, and, for the protection and response 
rates, also the significance level (z2-test), and the 
type-2-error which is the probability of concluding that 
a difference does not exist, when it does in reality. By 
lack of original data, the significance level of differences 
between the MFI-values of aged and young groups could 
not be recalculated and was taken from the original 
papers if given. 
Criteria for the detection of selection biases 
in the literature 
Several factors may influence the production of 
antibodies after vaccination: health state of the study 
subjects, intake of drugs at the time of vaccination, and 
history of exposition to influenza antigens prior to 
vaccination. Ignoring these factors introduces substantial 
biases into a trial. Therefore, we examined the selected 
papers for addressing and correcting these factors. 
Health state and use of drugs. Many acute and chronic 
illnesses (such as viral infections, malnutrition, renal and 
bone-marrow diseases etc.) and various drugs (such as 
analgesics, hormones, antimetabolites etc.) are known to 
impair the functions of the humoral immune system and 
should therefore l ad to exclusion from immune response 
trials 24. 
Prevaccination antibody. Specific or cross-reacting 
antibody against a given influenza strain present in high 
concentrations before vaccination with this strain, may 
suppress or impair the production of new antibody. 
According to this 'law of initial values '25 or 'negative 
feedback '26, the response to a given vaccine strain is 
inversely related to the specific prevaccination a tibody 
titre. Possibly, already circulating antibody combines 
with the vaccine to mask its recognition by immuno- 
competent cells, or, alternatively, switches off new 
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immunoglobulin synthesis by a more central mechanism 26. 
Therefore, when performing vaccination trials, one 
should carefully describe the prevaccination state of the 
study populations and analyse the data for different 
prevaccination classes, or exclude persons with high 
prevaccination titres. 
History of previous vaccinations. Vaccinations with 
heterologous influenza viruses in the past, even if they 
are no longer serologically detectable at the moment of 
the ungoing study (i.e. in the absence of prevaccination 
antibodies) may unpredictably influence the antibody 
production of the vaccine studied: sometimes a booster- 
effect is observed, sometimes a suppressive ffect 27. 
Subjects with previous vaccination should therefore be 
excluded. 
Results 
Papers to be reviewed, and data on study design 
The sources revealed 1805 titles for the combination 
of the keywords 'influenza' and 'vaccination'. Only 20 
papers met all our inclusion criteria. Many more papers 
dealt with influenza vaccination trials in the elderly but 
had not included control groups consisting of younger 
subjects. From the 20 selected papers, three 2s-3° were 
excluded because the anti-HA-IgG ELISA used did not 
discriminate between the different vaccine components. 
Data of seven studies published in the period 
1968-88 are presented in Table 1 in chronological order 
(years of performance of the trial, or, if this information 
had not been given, year of publication) 19'31-46. Most 
of the studies (10) were carried out in the United States 
of America. Only I0 studies (not shown) gave information 
about the seasonal relationship of the vaccination trial 
to natural influenza epidemics. Trials performed uring 
or shortly after epidemics with considerable impact 
would make it difficult to decide whether titre rises were 
due to the vaccine or to the natural virus. 
The period between collection of the pre- and 
postvaccination sera was usually 21-42 days (not shown); 
two studies 41'44 chose a shorter interval (14--15 days) 
which might be suboptimal, and two other papers 39'43 
did not give any information in that respect. As a 
technique for anti-HA-antibody determination, usually 
the haemagglutination inhibition test was performed, 
with the exception of Ref. 33 (neutralization test). 
As in many studies bi- or trivalent vaccines had been 
used, the seroresponse to,in total, 30 vaccine components 
could be studied separately. When using various vaccine 
types 34 or various dosages 19'42, the data on seroresponse 
were pooled, either by the authors themselves or by us, 
as there was a similar stratification among the study 
group of aged subjects and control groups. From 1967 
onwards, the antigenic ontents of commercial vaccines 
has been estimated by comparison with an international 
influenza A standard preparation and expressed in 
chicken cell agglutination (CCA) units (IU, international 
units). With the development of split and subunit 
vaccines, this technique became impracticable (see 
extremely high dosages in Refs. 38 and 39!) and was 
replaced by the single-radial immuno-diffusion test (#g 
haemagglutinin, HA) by the WHO in 1978 (for review 
see Ref. 47). 
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Table 1 Papers to be reviewed, and data on study designs 
Studyref ,,. Year b Place" Strain" 
Vaccines used 
Type* Dose t 
Gwaltney 31 1968 USA 
Marine s2 1968 USA 
Fulk 33 1968 USA 
Mostow TM ' 1969 USA 
CromwelP" 1969 USA 
Marine 35 1971 USA 
Howells 36 1971 UK 
Ruben 3' 1972 USA 
McKenzie 38 1973 AUS 
Feery ~ 1976 AUS 
Sarateanu "° 1977 FRG 
Hannoun 41 1977 FR 
Beare "= 1978 UK 
Phair "s 1978 USA 
Feery 44 1979 AUS 
Gross 45 1984 USA 
Gross "e 1985 USA 
A/Hong Kong/2/68 (H3N2) 
A/Aichi/2168 (H3N2) 
A/Aichi/2168 (H3N2) 
A/Japan/170/62 (H2N2) 
A/Aichi/2/68 (H3N2) 
AIAichi12168 (H3N2) 
AIAichi12168 (H3N2) 
A/Japan1305157 (H2N2) 
A/Hong Kong/2/68 (H3N2) 
B/Victoria/70 
A/Aichi/2/68 (H3N2) 
AIEngland142172 (H3N2) 
B/Hong Kong/8/73 
A/Port Chalmers/1/73 (H3N2) 
B/Hong Kong/8/73 
A/Victoria/3/75 (H3N2) 
A/New Jersey/8/76 (H1N1) 
A/New Jersey/8/76 (HIN1) 
A/New Jersey/8/76 (H1N1) 
A/New Jersey/8/76 (HIN1) 
AIVictoria13175 (H3N2) 
B/Hong Kong/8/73 
A/USSR/90/77 (HIN1) 
A/Texas/l/77 (H3N2) 
A/Philippines/2/82 (H3N2) 
AIChile11/83 (H1N1) 
B/USSR/1O0/83 
AIPhilippines/2182 (H3N2) 
A/Chile/l/83 (HIN1) 
BIUSSRI100183 
WV 
WV 
WV 
WV 
WV/SP 
WV 
WV 
SU 
SU 
SU 
WV 
WV 
WV 
SU 
SU 
SP 
SP 
400 CCA 
400 CCA 
4O0 CCA 
30013000 CCA 
30013000 CCA 
4O0 CCA 
1000 CCA 
10O0 CCA 
4OO CCA 
2O0 CCA 
700 CCA 
16 O00 CCA 
8 O00 CCA 
16 0O0 CCA 
360 CCA 
4OO CCA 
40O CCA 
2OO CCA 
4-61 #g 
200 CCA 
2O0 CCA 
25O CCA 
25O CCA 
250 CCA 
15#g 
15#g 
15#g 
15#g 
15/zg 
15/zg 
aFirst author and reference number of paper 
byear of performance of the study or, if not given, year of publication of paper 
CCountry of performance of the study 
aAbbreviated WHO-nomenclature of the virus strain used in the vaccine 
eVaccine type (WV, whole-virion; SU, subunit; NG, data not given) 
rVaccine doses (CCA, chicken cell agglutionation units; #g, microgram HA) 
gComment on study design. See appendix 
Data  on populations tudied 
Table 2 presents data to characterize the size, age range 
and prevaccination titres of the studied groups of aged 
and young subjects. The total numbers of groups varied 
from 1040 and 1133 up to437 and 20334, for elderly and 
young groups, respectively. The age distribution for the 
elderly usually reached from 60-70 up to 101 years of 
age; the young groups consisted of subjects either of 
a particular narrow age cohort (children 33, young 
adults 3z'41) or a very broad age range (< 65 years). Three 
studies 31'37'45 did not report any age range. The first one 
characterized the aged group only by the term 'elderly 
population', the latter two gave high mean ages (80 years, 
71-74 years). Another paper 33 presented an age range 
also including persons younger than 60 years but the text 
suggested that those subjects had been few. 
The elderly populations were usually recruited from 
old people's homes or geriatric institutions which was 
apparently reflected by the sex distribution: in all studies 
which gave data on that point, more female than male 
subjects had been included (not shown). 
For 20 vaccine components, the prevaccination state 
of aged and young groups could be compared. For 10 
strains, the elderly had a higher mean titre prior to 
vaccination; for four strains these values were equivocal, 
and in six instances the younger groups showed higher 
mean titres than the elderly. 
Serological results and statistical calculations 
Table 3 shows the results of the serological tests 
performed with pre- and postvaccination sera, and some 
basic statistical calculations. 
MFI-values for aged and young groups were present in 
all but one paper; transformed to a logarithmic scale, 
the MFI varied in a wide range between 0.2-1.4 for aged 
and 0.2-1.6 for young groups. For 15 of the 30 vaccine 
components, the authors themselves had given the 
significance l vel of the between-group differences for the 
MFI-values, which in none of these 15 cases was smaller 
than 5%. The significance l vel for the remaining papers 
could not be recalculated by us because of missing raw 
data in the papers. 
The protection and response rates were also hetero- 
genous, reaching from 16 to 93% for aged, and from 21 
to 100% for control groups. Between-group differences 
of protection rates could be calculated for 12 vaccine 
components, and of response rates for 16 vaccine 
components. Differences were only small for six protection 
rates and seven response rates and were not significant 
on a 5% level, but they had a high type-2-error (51-97%). 
In these cases, interpretation is difficult as it is not 
possible to decide whether (1) there really were no 
differences between age groups or, (2) there were 
differences, however, the studies were too insensitive (too 
small sample sizes) to detect hese. 
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Table 2 Data on the study group composition of 17 selected papers 
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Study a 
(Ref.) Strain No 
Aged Young 
Age Age 
range $1 b No range Sl b 
31 A/HK/68 80 
32 A/HK/68 31 
33 A/HK/68 16 
19 A/JAP/62 297 
A/HK/68 293 
34 A/HK/68 437 
35 A/HK/68 40 
A/JAP/57 36 
36 A/H K/68R 134 
B/VIC/70 
37 A/HK/68 57 
38 A/ENG/72 69 
39 B/HK/73 61 
A/PC/73 
40 B/H K/73 10 
A/VIC/75 
A/N J/76 
41 A/N J/76 73 
42 A/N J/76 84 
43 A/N J/76 72 
A/VIC/75 
44 B/HK/73 45 
A/USSR/77 
A/TEX/77 
45 A/PHIL/82 25 
A/CHILI83 
B/USSR/83 
46 A/PH I L/82 56 
A/CHILI83 
B/USSR/83 
NG c 1.1 53 NG 0.8 
67-99 1.3 23 23-25 0.6 
50-87 NG 11 6-14 NG 
> 65 1.5 545 < 65 1.7 
0.7 512 0.7 
NG NG 203 NG NG 
80-101 NG 70 6-31 NG 
NG NG 90 NG NG 
> 60 1.0 107 < 65 1.3 
0.8 1.0 
NG 1.8 17 NG 0.9 
60-79 1.1 231 15-59 1.0 
68-93 1.5 52 21-60 1.3 
2.3 2.0 
>60 0.3 67 2 59 0.6 
0.7 0.7 
1.0 0.2 
69-94 1.4 57 18-20 0.3 
/>65 1.9 372 13-65 NG 
60-95 1.4 20 <45 NG 
1.2 NG 
66-100 NG 47 25-64 NG 
NG NG 
NG NG 
NG 1.3 21 NG 1.3 
1.3 1.5 
1.4 1.5 
> 65 1.3 45 < 65 1.3 
1.8 1.4 
1.7 1.5 
aComment on group composition. See appendix 
bprevaccination mean titre of the entire group (decadic logarithm) 
CData not given (NG) 
There were also significant between-group differences, 
6 for the protection rate and 9 for the response rate, 
associated with a low (< 1-5%, 8 cases) or intermediate 
(1642%,  6 cases) type-2-error. For some vaccine 
components, a more favourable immune response for 
the young groups was revealed (significantly negative 
differences: 2 for PR and 8 for RR). However, also 
contrary results could be found (significantly positive 
differences: 4 for PR and 1 for RR). 
Thus, a heterogeneous picture could be obtained, with 
more insignificant and significant results in favour of 
young subjects, which suggests a slight tendency. 
An attempt o combine the pattern of MFI, PR and 
RR per vaccine component o obtain a tendency per 
paper is shown in the last column of Table 3. Where the 
absolute differences of all given seroresponse measures 
had the same sign, this sign was used to indicate a 
tendency (either ' - '  for a better immune response of 
younger groups, or '+ '  for the alternative case). Where 
one of the given seroresponse measures was significant 
on the 5% level, the sign was doubled (either ' -  - '  or 
'+ +'). Where the different seroresponse measures 
showed insignificant differences with different signs, this 
was expressed as '0' (no tendency detected). 
Table 4 presents the 30 cases assessed in this way. For 
16 cases, a 'significant' difference between the age groups 
was not detected (sum of cases indicated as ' - ' ,  '+ '  and 
'0'). However, most of these (9 cases) suggest a slight 
tendency in favour of young age groups. This is supported 
by 10 cases with a clear t.endency in favour of young 
groups, versus only four in favour of aged groups. The 
distribution of these results according to types or 
subtypes of virus strains does not reveal additional 
information for influenza A-H 1N 1, A-H2N2 and influenza 
B, because of the small number of cases per type/subtype. 
For influenza A-H3N2, results are contradictory, presenting 
both 3 'significant' cases in favour of young groups, and 
of aged groups, respectively. 
Selection biases and combinability of  serological 
results 
Table 5 addresses three important criteria for group 
composition which should have been obeyed by the 
papers: absence of illness and drugs influencing the 
immune system, no previous influenza vaccinations, and 
stratification for or exclusion of protective prevaccination 
titres (or presentation of data in a way that this would 
be possible in retrospect). The documentation of these 
data was very incomplete in virtually all papers. In six 
cases it was stated, at least, that the study populations 
were clinically healthy. Two other papers reported that 
it dealt in part with 'chronically ill' subjects which did 
not lead to their exclusion. Another paper 4s included 
children and young adults with cystic fibrosis as a control 
group. Only eight studies stated that the vaccinees, in 
the course of the study, had not used drugs influencing 
the immune system. Four papers reported that some of 
the participants had received other influenza vaccinations 
in previous years which, however, did not lead to 
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Table 4 Tendency of 17 selected papers to detect differences between 
aged and young study groups, subdivided for types and subtypes of 30 
vaccine strains 
Tendency a 
Type/sub~pe 
of vaccine strain - - - 0 + + + 
A-H1N1 3 2 1 1 
A-H2N2 2 
A-H3N2 3 5 3 1 3 
B 2 2 2 
TotaP 10 9 5 2 4 
--, seroresponse variables higher for young group ( - - ,  including 
significant differences); +,  seroresponse variables higher for aged group 
(+ +, including significant differences); 0, no tendency 
bNumber of vaccine strains 
exclusion of those subjects. Only one paper dealt 
expressis verbis with previously unvaccinated subjects. 
Thus, of the 17 controlled studies, none was free of any 
bias and 16 failed to address two or three criteria. 
As the papers revealed a substantial heterogeneity in 
view of group composition and distribution of main 
biases which could not be corrected for, it did not 
appear to be possible to combine or pool the data on 
serological response (Table 3) in the sense of meta- 
analysis techniques. 
Discussion 
Influenza viruses are a major cause of mortality and 
serious morbidity in the elderly. Therefore, recommen- 
dations for the use of influenza vaccines have been given 
in several countries. Is vaccination really effective in this 
age-group? It is widely believed that, in the elderly, the 
ability to produce a sufficient amount of antibody after 
administration f bacterial and viral vaccines, isdecreased, 
alongside with other age-related changes of the entire 
immune system. Early support for this impression came 
from the classical study of Sabin et al. 48 describing a 
lower immune response in aged people to Japanese B 
encephalitis virus vaccine, as compared to children. This 
paper has been cited frequently, but the observations of 
Sabin are based on 20 children and 20 aged individuals 
only, with a different history of previous expositions to 
the pathogen. Other support comes from field trials 
measuring the protection acquired by vaccination, 
against the naturally occurring pathogens (usually 
influenza viruses and Streptococcus pneumoniae), often 
suggesting a lower vaccine effectiveness in the elderly as 
compared to younger subjects. However, such studies 
usually struggle with methodological flaws 8'49. 
Only a few studies have been published which compare 
the seroresponse of different age groups to vaccines other 
than influenza. Results, as a working paper of the World 
Health Organization pointed out, are 'still incomplete 
and are often contradictory '15. Ammann et al. 5° in testing 
a bivalent Streptococcus pneumoniae vaccine, found lower 
absolute antibody titres but a still sufficient protection 
rate, in a group of 66 elderly persons, as compared to 
20 young adults. Musher et al. 51 described 10 healthy 
young adults and five aged patients with chronic 
pulmonary disease after polyvalent Streptococcus pneu- 
moniae vaccination and saw no significant differences in 
absolute postvaccination antibody titres, but a lower 
Influenza vaccines in the elderly: W.E.P. Beyer et al. 
opsonizing activity, in the sera of the elderly. Other 
papers on Streptococcus pneumoniae vaccination not 
including young control groups, report satisfying antibody 
development in the aged 52-57. Solomonova nd Vizev 5a 
detected a slightly delayed antibody production after 
vaccination with tetanus toxoid in aged subjects as 
compared to subjects aged 40-60 years. The difference, 
however, was not significant. In 70 non-dialysed elderly 
individuals, Denis et al. 59 found a profoundly impaired 
seroresponse to hepatitis B vaccine. 
In an attempt to reveal, from the recent literature, the 
association between high age and the ability to produce 
specific antibodies after influenza vaccination, we could 
not detect a clear answer, but a tendency only: for 10 
out of 30 single vaccine components, tatistical calcu- 
lations suggest a lower response of the elderly, as 
compared to younger control subjects. Another 9 cases 
support his tendency but show insignificant differences 
between age groups only. On the other hand, some 
contradictory esults exist as well (elderly more favourable 
than young in 4 cases). 
We showed that virtually all studies reviewed by us 
insufficiently controlled two major groups of biases: 
differences in health state and differences in previous 
exposure to influenza ntigens. The general direction of 
these selection biases is such that failure to control these 
leads to an underestimation f the response of the elderly: 
in this age group, the prevalence of disease and drug use 
influencing the immune system, the chance of previous 
vaccinations, and the mean titres of prevaccination 
antibody, are generally higher. Neglecting these factors 
during the selection of the study subjects has introduced 
a considerable heterogeneity in the study groups of the 
papers reviewed and has also seriously affected the 
validity of the described results which may then give an 
idea about the overall condition of the group studied, 
but cannot lead to conclusions concerning fundamental 
age-related changes in the immune system. Although we 
saw a tendency supporting a decreased seroresponse in
Table 5 Selection biases present in 17 papers 
Corrected for 
Study Health Vacc. Prevacc. 
(Ref.) state a history ~ state c 
31 No No Yes 
32 No No No 
33 Yes No No 
19 No No No 
34 Yes No No 
35 No No No 
36 No Yes No 
37 No No Yes 
38 No No Yes 
39 No No No 
40 No No No 
41 No No No 
42 No No No 
43 Yes No Yes 
44 No No No 
45 No No No 
46 No No No 
aSubjects excluded who had diseases or used drugs which may influence 
immune response 
bSubjects excluded who had a history of previous influenza vaccinations 
cSubjects excluded who had high (protecting) prevaccination titres 
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Table 6 Selection and stratification criteria for influenza vaccination 
trials 
Criterium Controlled by 
Health state 
Vaccination history 
Prevaccination antibody 
Primidg 
Senieur protocol 2" 
Exclusion of subjects previously 
immunized with any influenza vaccine 
Exclusion of subjects with high/ 
protective homologous serum antibody 
prior to vaccination 
Stratification according to priming 
periods (see Table 7) 
the elderly, the high prevalence of biases does not justify 
any generalization. The association between high age and 
responsiveness to influenza vaccines, if any, has not yet 
been established. 
In this paper, we have used basic statistical methods 
analogous to another eview on influenza vaccinology: 
Gross et al. 6° reviewed 12 studies on the effects of cancer 
chemotherapy on the seroresponse to influenza vaccines 
and found that in eight papers a significantly lower 
antibody development in subjects on treatment, as 
compared to untreated control subjects, had been 
established. Moreover, they detected a high type-2-error 
in the remaining four studies which could not find any 
significant effects of chemotherapy which was probably 
due to insensitivity rather than to the absence of such 
differences. In contrast o the definite results of Gross 
et al., our results are more heterogeneous, even taking 
into account hat many papers in our review had also a 
high type-2-error. The main distinction between the two 
reviews appears to be the fact that in the studies included 
by Gross et al., there was usually no major difference in 
age distribution, and, as a consequence, the two major 
groups of biases, differences in health state and in 
previous exposure to influenza antigens, were avoided. 
Based on the considerations in the section Materials 
and methods of this review, we suggest admission criteria 
for future immune response studies in the elderly as 
described 'in Table 6. To define the health state of 
vaccinees, general criteria such as 'apparently healthy' 
or 'without overt diseases' are insufficient o exclude 
underlying disease, as pointed out by Ligthart et al. 24. 
Therefore the strict 'Senieur Protocol: Admission criteria 
for immunogerontological studies in man' should be used 
as it includes clearly defined anamnestic and clinical 
information, laboratory data and drug interference. 
Subjects previously immunized with any hetero- or 
homologous influenza vaccines, and subjects who do not 
clearly remember, are to be excluded. Subjects with 
high/protective serum antibody prior to vaccination, 
specifically directed against he vaccine component, are 
to be excluded. The exclusion threshold may be 
dependent on the antibody detection method used. 
In contrast to the three criteria mentioned above which 
can be controlled by an appropriate study design, the 
age-related exposition to different influenza A subtypes 
is a factor which cannot be controlled. However, it 
strongly influences the immune response to vaccination 
even dozens of years later. Table 7 shows the natural 
occurrence of haemagglutinin subtypes from 1889 
onwards, as has been established by seroepidemiological 
studies and, from 1933 onwards, by direct isolations in 
man 61. In particular, the first influenza A infection during 
Table 7 Influenza A prevalence and priming eras 
Haemagglutinin Period of Priming period 
subtype prevalence (birth years) 
H2 1889-1899 - 1877 
H3 1890-1917 a 1878-1905 
Hsw 1918-1925 1906-1920 
? 1926-1932 1921-1927 
H0 b 1933-1946 1926-1939 
H 1 1947-1957 1940-1949 
H2 1956-1967 1950-1961 
H3 1968- a 1962- 
a1908-1918, and 1978- co-circulation of H3 and H161 
~According to WHO-nomenclature of 1971. In the new nomenclature 
of 1980, Hsw, H0, and H1 are expressed as H1 
lifetime ('priming') is of interest. It usually occurs at an 
age between 5 and 15 years and results in a potent 
immunological memory for the subtype to which the 
infective strain belongs. Individuals primed by a special 
subtype, react differently to later homologous or hetero- 
logous infections or vaccinations than those primed for 
another subtype (the doctrine of 'original antigenic 
sin'62). Therefore, age cohorts can be established 
according to primary infection. Table 7 presents the 
distribution of Marine and Thomas 35, based on 687 
persons of all ages in the United States in 1971 which 
has largely been confirmed by Masurel and Andre 
(1978) 63 who studied a population of 403 subjects in The 
Netherlands in 1977. The existence of age cohorts with 
differing natural exposure histories questions the validity 
of the general definition of 'aged' or 'elderly' as being 60 
years of age or more, and suggests the necessity of a more 
differentiated age stratification according to the priming 
periods. 
We believe that the use of strict selection and 
stratification criteria is mandatory if one wishes to study 
ageing per se. More knowledge of the latter is needed to 
develop appropriate strategies to protect elderly who do 
suffer from diseases and who have an increased risk 
of acquiring complications during or after influenza 
infection. 
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Appendix 
Comments 
Gwaltney et aI.31: 
Four study groups were described: 'spray group', 'control 
group', 'combined group' and 'gun group'. Only the latter 
two were included here. Data for the neutralization test 
were not included. PR and RR were read from Figure I. 
Marine et al.32: 
MFI-values were read from Figures 2 and 3. 
Fulk et al.33: 
Groups vaccinated either locally, or parenterally, were 
described. Only the latter ones were included here. Log2 
values in Table I of the original papers were transformed 
to log10 values. 
Mostow et al.19: 
Data for 'prison group (GSP)' and 'school group (OCS)' 
were pooled to form the young group here. Table 5, which 
presented the seroresponse, gave only percentages 
without the appropriate denominators. These had partly 
to be taken from Table 1 of the original paper, partly to 
be calculated using a short information, in brackets, in 
Materials and methods. 
Marine and Thomas35: 
Groups 1 and 2 (birth date 1940-1965), but not group 
3 (birth date 1892-1939) of Table 4 of the original paper 
were pooled to form the young group here. 
Howells et al.36: 
Vaccination trials from 1971 to 1973 were described. Only 
data for 1971 were included here. The data for the young 
group came from a different paper 64. Only seroconversion 
from negative prevaccination titres to postvaccination 
titres greater than 10, and mean postvaccination titres 
were given. 
Ruben a7: 
Also Ref. 65 was reviewed (identical experiment). In the 
original paper, bivalent vaccine (A/Aichi/2/68 and 
B/Mass/I/71) was described, but no data were presented 
for the latter strain. It should be mentioned that 
vaccination of the control group had been performed one 
year earlier and with a higher vaccine dose. 
Mackenzie 38 : 
A bivalent vaccine (A/England/42/72 and B/Roma/1/67) 
was used, but no data were presented for the latter strain. 
In Tables I I I  and IV  of the original paper, primary and 
booster vaccination were combined while, in the first two 
Tables, the effects of both injections could be studied 
separately. Moreover, the authors included only sero- 
responders in Tables I I I  and IV  of the original paper. 
Sarateanu et al.4°: 
Age groups 'I- I I I '  of the original paper were pooled to 
form the young group. 
Hobson et al.26: 
A trivalent vaccine (A/New Jersey/8/76, A/Victoria/75 
and B/Hong Kong/2/8/73) was used, but no data were 
presented for the latter two strains. Calculation of 
51:0.5 log 5 for negative sera. In forming the young group, 
only data of young persons receiving the identical doses 
as aged subjects (200 CCA), were used. 
The Pandemic Working Group etc.4Z: 
The numbers and percentages of Tables 2, 3 and 4 of the 
original paper did not fit well. For example, in Table 3, 
11% of the subjects > 65 years had a prevaccination titre 
greater than 10 but in Table 4, 13%. 
Feery et ai.44: 
The young group was formed only by the group named 
'adults' in the original paper; another group named 
'young adults' was excluded here because these subjects 
had received a booster immunization. 
Gross et al.45: 
Two more aged groups were vaccinated with higher doses 
of the trivalent split vaccine, and three more groups with 
different doses of a whole virus vaccine. The total number 
of persons was 148, divided into six groups. The mean 
ages of the groups ranged between 71 and 74 years. The 
control groups were children and young adults with cystic 
fibrosis. For our calculations, we used the data of Table 2 
of the original paper. Protection rates could not be 
recalculated as numbers of protected subjects before 
vaccination were not given. 
Gross et al.46: 
Two more aged groups (C and D in Table I of the original 
paper) were vaccinated with whole virus vaccine. These 
data were excluded because of the lack of a young 
reference group. Data on booster vaccination in the 
elderly were excluded. The numbers of aged groups 
vaccinated with split vaccine in Tables I and 2 (n = 56), 
and Table 3 (n = 25) of the original paper differ. For our 
calculations, we used the data of Tables 1 and 2 of 
the original paper. 
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